Formosa Laboratories (4746) Fundamentals 2026 — P/E 18.3x, Revenue Analysis | SniperIQ
Formosa Laboratories (4746) is a TW-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of NT$6.3B, trading at NT$52.10 on the TAI. This SniperIQ fundamentals page covers Formosa Laboratories's valuation (P/E 18.3x, P/B 0.8x), profitability (net margin 7.1%), revenue (NT$4.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Formosa Laboratories's market cap?
Formosa Laboratories (4746) has a market capitalization of approximately NT$6.3B, trading at NT$52.10 on the TAI. Market cap moves with the live share price.
What is Formosa Laboratories's P/E ratio?
Formosa Laboratories's trailing twelve-month P/E ratio is 18.3x, with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Formosa Laboratories?
Formosa Laboratories runs a net profit margin of 7.1%, a gross margin of 42.0%, and an operating margin of 16.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Formosa Laboratories generate?
Formosa Laboratories reported revenue of NT$4.9B for fiscal year 2025, with net income of NT$441M and earnings per share (EPS) of 3.67. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Formosa Laboratories pay a dividend?
Formosa Laboratories offers a trailing dividend yield of about 5.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Formosa Laboratories financially healthy?
Formosa Laboratories carries a debt-to-equity ratio of 0.46x and a current ratio of 2.33x, with a market beta of 0.52. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Formosa Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Formosa Laboratories (4746) the key facts are: market cap NT$6.3B, P/E 18.3x, revenue NT$4.9B, 52-week range 50-72. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Formosa Laboratories's full fundamentals live
Get Formosa Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.